No Validated Scoring System Exists to Differentiate Alcohol from MASLD in Decompensated Cirrhosis
There is currently no validated scoring system that can reliably differentiate alcoholic cirrhosis from MASLD in patients with decompensated cirrhosis. The available evidence shows that while some exploratory tools exist, none have been validated for this specific purpose in the decompensated setting.
Current Evidence Landscape
The EASL guidelines explicitly state that MELD remains the recommended prognostic tool for prediction of short-term mortality and morbidity in decompensated cirrhosis 1, but this score predicts outcomes rather than differentiating etiologies. The guidelines acknowledge that "we cannot at this point make any aetiology-specific recommendations regarding prognostic markers in alcohol-related, compensated liver disease" 1, and this limitation extends even more severely to decompensated disease.
Exploratory Tools Under Investigation
The ANI Score
A 2026 pilot study evaluated the ALD/NAFLD index (ANI) score in patients with steatotic liver disease 2. However, this study:
- Only examined patients with MASLD (not decompensated cirrhosis)
- Explicitly states "the ANI score is not validated to distinguish MetALD from MASLD" 2
- Cannot be applied to your clinical scenario
AST/ALT Ratio
Recent comparative analysis suggests the AST/ALT ratio >1.5 was present in 62% of AFLD versus 28% of MASLD 3. While exploratory ROC analysis yielded an AUC of 0.88, this study:
- Was cross-sectional with only 30 patients per group
- Did not specifically examine decompensated cirrhosis
- Requires external validation with objective alcohol biomarkers 3
- Shows significant overlap between groups
Clinical Approach in Decompensated Cirrhosis
Since no scoring system can differentiate etiologies, diagnosis must rely on comprehensive alcohol assessment:
Alcohol Use Assessment (Essential)
- Patient interview with validated questionnaires (AUDIT-C, CAGE)
- Objective biomarkers: Phosphatidylethanol (PEth) testing is critical—it was positive in 69.4% of MetALD patients who might otherwise be misclassified 4
- Serial measurements over ≥3 months to establish consumption patterns 5
Diagnostic Thresholds
According to the 2026 AGA Clinical Practice Update 5:
- MASLD: <140 g/week (women) or <210 g/week (men)
- MetALD: 140-350 g/week (women) or 210-420 g/week (men)
- ALD: >350 g/week (women) or >420 g/week (men)
Biochemical Patterns (Suggestive but Not Diagnostic)
While not validated for differentiation in decompensated cirrhosis:
- MASLD pattern: Higher ALT elevations, AST/ALT ratio typically <1 3
- ALD pattern: AST/ALT ratio >1.5 more common, mild hypoalbuminemia 3
- Critical caveat: These patterns overlap significantly and cannot be used alone for diagnosis
Important Clinical Pitfalls
Liver stiffness measurements are unreliable during active alcohol use—they transiently increase stiffness values and should be interpreted cautiously 5
Underreported alcohol consumption is common—PEth testing improved ascertainment of alcohol exposure and proper phenotyping 4
MetALD represents a distinct high-risk phenotype—patients with both metabolic dysfunction and alcohol use have worse outcomes than MASLD alone, with 23% increased MACE and 34% increased mortality 6
Prognostic scores differ from diagnostic scores—while MELD, CLIF-C-AD, and MELD-Na predict mortality in decompensated cirrhosis 1, 7, they do not differentiate etiology
Bottom Line for Clinical Practice
You cannot use a scoring system to differentiate these etiologies in decompensated cirrhosis. Instead, establish diagnosis through:
- Quantified alcohol consumption history over ≥3 months
- PEth testing for objective verification
- Assessment of cardiometabolic risk factors
- Recognition that many patients have overlapping etiologies (MetALD)
The distinction matters clinically because alcohol abstinence is independently associated with recompensation (sHR 1.87) and ongoing consumption increases mortality 5-fold 4, making accurate phenotyping essential for management rather than just prognostication.